Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

Visit https://www.peervoice.com/TGP860 to view the entire programme with slides. After completing “Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition”, participants will be able to: Summarise the benefits and limitations of current treatment strategies used in the management of chronic inflammatory demyelinating polyneuropathy (CIDP); Describe the mechanistic rationale for therapies targeting the complement pathway in CIDP; Appraise the clinical safety and efficacy data from trials examining novel complement inhibitors in patients with CIDP; and Evaluate key patient and disease characteristics to assess suitability for novel complement inhibitors in CIDP.